Loading…
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $21.8B | $5.0B | $1.7B | $2.7B | 6.6% | 8.2% | -1.6% |
| 2024 | $20.2B | $4.8B | $1.7B | $3.1B | 6.6% | 4.2% | 14.9% |
| 2023 | $19.4B | $4.4B | $1.5B | $2.1B | 5.8% | 2.7% | -16.6% |
| 2022 | $18.9B | $4.4B | $1.8B | $1.7B | 7.0% | - | - |
| 2021 | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 18,870 | 19,372 | 20,178 | 21,840 |
| Operating Revenue | - | 18,870 | 19,372 | 20,178 | 21,840 |
| Cost Of Revenue | - | 10,393 | 11,202 | 11,053 | 11,915 |
| Gross Profit | - | 8,477 | 8,170 | 9,125 | 9,925 |
| Operating Expense | - | 6,002 | 5,746 | 6,269 | 6,939 |
| Research And Development | - | 1,256 | 1,237 | 1,190 | 1,265 |
| Selling General And Administration | - | 4,709 | 4,719 | 4,857 | 5,278 |
| Total Expenses | - | 16,395 | 16,948 | 17,322 | 18,854 |
| Operating Income | - | 2,475 | 2,424 | 2,856 | 2,986 |
| Total Operating Income As Reported | - | 2,282 | 2,111 | 2,397 | 2,579 |
| EBITDA | - | 4,410 | 4,402 | 4,819 | 4,956 |
| Normalized EBITDA | - | 4,689 | 4,754 | 5,319 | 5,416 |
| EBIT | - | 2,181 | 2,114 | 2,533 | 2,494 |
| Interest Income | - | 16 | 49 | 163 | 38 |
| Interest Expense | - | 398 | 452 | 528 | 613 |
| Net Interest Income | - | -382 | -403 | -365 | -575 |
| Other Non Operating Income Expenses | - | -29 | -7 | 14 | -71 |
| Other Income Expense | - | -308 | -359 | -486 | -531 |
| Interest Income Non Operating | - | 16 | 49 | 163 | 38 |
| Interest Expense Non Operating | - | 398 | 452 | 528 | 613 |
| Net Non Operating Interest Income Expense | - | -382 | -403 | -365 | -575 |
| Pretax Income | - | 1,783 | 1,662 | 2,005 | 1,881 |
| Tax Provision | - | 148 | 132 | 300 | 203 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -23.16 | -27.81 | -75 | -49.68 |
| Net Income Continuous Operations | - | 1,635 | 1,530 | 1,705 | 1,678 |
| Net Income From Continuing And Discontinued Operation | - | 1,779 | 1,484 | 1,705 | 1,678 |
| Net Income From Continuing Operation Net Minority Interest | - | 1,635 | 1,530 | 1,705 | 1,678 |
| Net Income | - | 1,779 | 1,484 | 1,705 | 1,678 |
| Net Income Common Stockholders | - | 1,689 | 1,424 | 1,705 | 1,678 |
| Net Income Including Noncontrolling Interests | - | 1,779 | 1,484 | 1,705 | 1,678 |
| Normalized Income | - | 1,890.84 | 1,854.19 | 2,130 | 2,088.32 |
| Diluted NI Availto Com Stockholders | - | 1,689 | 1,424 | 1,705 | 1,678 |
| Basic Average Shares | - | 285 | 286.28 | 289.76 | 287.65 |
| Diluted Average Shares | - | 287.36 | 288.39 | 291.01 | 288.51 |
| Reconciled Depreciation | - | 2,229 | 2,288 | 2,286 | 2,462 |
| Reconciled Cost Of Revenue | - | 10,393 | 11,202 | 11,053 | 11,915 |
| Total Unusual Items | - | -279 | -352 | -500 | -460 |
| Total Unusual Items Excluding Goodwill | - | -279 | -352 | -500 | -460 |
| Preferred Stock Dividends | 90 | 90 | 60 | - | - |
| Net Income Discontinuous Operations | - | 144 | -46 | 0 | 0 |
| Special Income Charges | - | -216 | -313 | -458 | -408 |
| Other Special Charges | 178 | 24 | - | - | - |
| Restructuring And Mergern Acquisition | - | 192 | 313 | 458 | 408 |
| Gain On Sale Of Security | - | -63 | -39 | -42 | -52 |
| General And Administrative Expense | 1 | - | - | - | - |
| Salaries And Wages | 1 | - | - | - | - |
| Other Operating Expenses | - | 37 | -210 | 222 | 396 |
| Selling And Marketing Expense | 4,867 | - | - | - | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Becton, Dickinson and Companythis co. | BDX | $41.2B | 24.56↓ discount | 1.62 | 6.6% | 12.06 |
| Edwards Lifesciences Corporation | EW | $50.4B | 46.91 | 4.87 | 10.4% | 33.19 |
| Cardinal Health, Inc. | CAH | $47.2B | 30.27 | -16.99 | -56.1% | 16.71 |
| IDEXX Laboratories, Inc. | IDXX | $44.5B | 42.05 | 27.75 | 66.0% | 30.06 |
| Humana Inc. | HUM |
| - |
| - |
| - |
| - |
| - |
| - |
| $42.0B |
| 35.35 |
| 2.38 |
| 6.7% |
| - |
| Alnylam Pharmaceuticals, Inc. | ALNY | $40.5B | 129.21 | 51.37 | 39.8% | 61.62 |
| Agilent Technologies, Inc. | A | $39.1B | 29.99 | 5.80 | 19.3% | 22.15 |
| Waters Corporation | WAT | $37.0B | 57.52 | 14.43 | 25.1% | 36.74 |
| Zoetis Inc. | ZTS | $33.3B | 12.47 | 10.01 | 80.2% | 9.90 |
| Peer Median | - | 38.70 | 7.90 | 22.2% | 30.06 | |